NDAINHALATIONAEROSOL, METERED
Approved
Dec 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TILADE (nedocromil sodium) is an inhaled aerosol anti-inflammatory agent approved in 1992 for asthma management. It functions as a mast cell stabilizer and inhibitor of inflammatory mediator release, reducing airway hyperresponsiveness. The drug is used as maintenance therapy and for prevention of asthma symptoms in patients with mild to moderate persistent asthma.
LOE Approaching
As a 30+ year-old product approaching loss of exclusivity, TILADE faces significant commercial headwinds with minimal active career growth and downsizing commercial infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TILADE offers limited career growth due to its LOE-approaching status and zero linked job postings, indicating a shrinking team and declining organizational investment. Professionals on this product should prepare for portfolio rotation or career transitions as the brand enters post-LOE management.
Brand ManagerField Sales Representative
Worked on TILADE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.